BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 29650531)

  • 1. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
    Senni N; Savall M; Cabrerizo Granados D; Alves-Guerra MC; Sartor C; Lagoutte I; Gougelet A; Terris B; Gilgenkrantz H; Perret C; Colnot S; Bossard P
    Gut; 2019 Feb; 68(2):322-334. PubMed ID: 29650531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
    Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
    J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.
    Gougelet A; Sartor C; Senni N; Calderaro J; Fartoux L; Lequoy M; Wendum D; Talbot JN; Prignon A; Chalaye J; Imbeaud S; Zucman-Rossi J; Tordjmann T; Godard C; Bossard P; Rosmorduc O; Amaddeo G; Colnot S
    Gastroenterology; 2019 Sep; 157(3):807-822. PubMed ID: 31194980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
    Liang Y; Feng Y; Zong M; Wei XF; Lee J; Feng Y; Li H; Yang GS; Wu ZJ; Fu XD; Feng GS
    Hepatology; 2018 May; 67(5):1807-1822. PubMed ID: 29152756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
    Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
    Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBx regulates fatty acid oxidation to promote hepatocellular carcinoma survival during metabolic stress.
    Wang MD; Wu H; Huang S; Zhang HL; Qin CJ; Zhao LH; Fu GB; Zhou X; Wang XM; Tang L; Wen W; Yang W; Tang SH; Cao D; Guo LN; Zeng M; Wu MC; Yan HX; Wang HY
    Oncotarget; 2016 Feb; 7(6):6711-26. PubMed ID: 26744319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways.
    Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
    J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
    Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
    J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.
    Ando S; Shibahara J; Hayashi A; Fukayama M
    Virchows Arch; 2015 Nov; 467(5):535-42. PubMed ID: 26311355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
    Carotenuto P; Fassan M; Pandolfo R; Lampis A; Vicentini C; Cascione L; Paulus-Hock V; Boulter L; Guest R; Quagliata L; Hahne JC; Ridgway R; Jamieson T; Athineos D; Veronese A; Visone R; Murgia C; Ferrari G; Guzzardo V; Evans TRJ; MacLeod M; Feng GJ; Dale T; Negrini M; Forbes SJ; Terracciano L; Scarpa A; Patel T; Valeri N; Workman P; Sansom O; Braconi C
    Gut; 2017 Jul; 66(7):1268-1277. PubMed ID: 27618837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.
    Tao J; Xu E; Zhao Y; Singh S; Li X; Couchy G; Chen X; Zucman-Rossi J; Chikina M; Monga SP
    Hepatology; 2016 Nov; 64(5):1587-1605. PubMed ID: 27097116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Catenin signaling in hepatocellular carcinoma.
    Xu C; Xu Z; Zhang Y; Evert M; Calvisi DF; Chen X
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia.
    Suarez M I; Uribe D; Jaramillo CM; Osorio G; Perez JC; Lopez R; Hoyos S; Hainaut P; Pineau P; Navas MC
    Ann Hepatol; 2015; 14(1):64-74. PubMed ID: 25536643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.
    Zucman-Rossi J; Benhamouche S; Godard C; Boyault S; Grimber G; Balabaud C; Cunha AS; Bioulac-Sage P; Perret C
    Oncogene; 2007 Feb; 26(5):774-80. PubMed ID: 16964294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma.
    Okabe H; Delgado E; Lee JM; Yang J; Kinoshita H; Hayashi H; Tsung A; Behari J; Beppu T; Baba H; Monga SP
    PLoS One; 2014; 9(6):e98817. PubMed ID: 24892551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness.
    Cadoux M; Caruso S; Pham S; Gougelet A; Pophillat C; Riou R; Loesch R; Colnot S; Nguyen CT; Calderaro J; Celton-Morizur S; Guerra N; Zucman-Rossi J; Desdouets C; Couty JP
    J Hepatol; 2021 Jun; 74(6):1386-1397. PubMed ID: 33484773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.